Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our top-notch dedicated system is used to design specialised libraries for receptors.
Fig. 1. The sreening workflow of Receptor.AI
The method involves detailed molecular simulations of the receptor in its native membrane environment, with ensemble virtual screening focusing on its conformational mobility. When dealing with dimeric or oligomeric receptors, the whole functional complex is modelled, and the tentative binding pockets on and between the subunits are established to address all possible mechanisms of action.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q01726
UPID:
MSHR_HUMAN
Alternative names:
Melanocortin receptor 1
Alternative UPACC:
Q01726; Q66K38; Q6UR93; Q8WWX6; Q8WWX7; Q96I33; Q96RU4; Q9UBF7; Q9UN58; Q9UN59; Q9UN60; Q9UN61; Q9UN62
Background:
The Melanocyte-stimulating hormone receptor, also known as Melanocortin receptor 1, plays a pivotal role in skin pigmentation. It binds to melanocortin, including MSH and ACTH, triggering a cascade via G proteins that activates adenylate cyclase, crucial for melanogenesis. This process regulates the production of eumelanin and phaeomelanin, determining skin, hair, and eye color.
Therapeutic significance:
Given its association with cutaneous malignant melanoma 5, understanding the Melanocyte-stimulating hormone receptor's function could unveil novel therapeutic avenues. Its role in melanogenesis makes it a potential target for treatments aimed at modulating pigmentation disorders and skin cancer.